诊断时 CD70 过表达预测滤泡性淋巴瘤复发并支持 CD19-CD70 双靶点 CAR-T 治疗
CD70 Overexpression at Diagnosis Predicts Relapse and supports dual CD19-CD70 CAR-T Therapy in Follicular Lymphoma.
ALL SOURCES
CD70 Overexpression at Diagnosis Predicts Relapse and supports dual CD19-CD70 CAR-T Therapy in Follicular Lymphoma.
Sensitive CAR T cells redefine targetable CD70 expression in solid tumors.
Beyond Hematology-Current Insights into Chimeric Antigen Receptor (CAR) T-Cell Therapy for Skin and Connective Tissue Disorders.
Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma.
CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy.
Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatment
Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods.
Engineering off-the-shelf universal CAR T cells: A silver lining in the cloud.
CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19.
共 10 条
MEMBER ACCOUNT
登录成功会直接打开下一页。